JP2009256381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009256381A5 JP2009256381A5 JP2009183888A JP2009183888A JP2009256381A5 JP 2009256381 A5 JP2009256381 A5 JP 2009256381A5 JP 2009183888 A JP2009183888 A JP 2009183888A JP 2009183888 A JP2009183888 A JP 2009183888A JP 2009256381 A5 JP2009256381 A5 JP 2009256381A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- dosage
- inhibitor
- group
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims 34
- 239000013543 active substance Substances 0.000 claims 14
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 8
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 7
- 239000011324 bead Substances 0.000 claims 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 7
- 239000008187 granular material Substances 0.000 claims 7
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 6
- 239000005541 ACE inhibitor Substances 0.000 claims 6
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 6
- 239000003826 tablet Substances 0.000 claims 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 5
- 108010061435 Enalapril Proteins 0.000 claims 5
- 108010007859 Lisinopril Proteins 0.000 claims 5
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 5
- 239000002775 capsule Substances 0.000 claims 5
- 229960000873 enalapril Drugs 0.000 claims 5
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 229960002394 lisinopril Drugs 0.000 claims 5
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 5
- 229960004844 lovastatin Drugs 0.000 claims 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 5
- 239000006186 oral dosage form Substances 0.000 claims 5
- 229960003401 ramipril Drugs 0.000 claims 5
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 5
- 229960002855 simvastatin Drugs 0.000 claims 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 5
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 4
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 4
- 229960005370 atorvastatin Drugs 0.000 claims 4
- 229960000830 captopril Drugs 0.000 claims 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 4
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 229960003765 fluvastatin Drugs 0.000 claims 4
- 235000019152 folic acid Nutrition 0.000 claims 4
- 239000011724 folic acid Substances 0.000 claims 4
- 229960002490 fosinopril Drugs 0.000 claims 4
- 229960002965 pravastatin Drugs 0.000 claims 4
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 4
- 229960001455 quinapril Drugs 0.000 claims 4
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 4
- 229960002051 trandolapril Drugs 0.000 claims 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 3
- 229960000304 folic acid Drugs 0.000 claims 3
- 230000036454 renin-angiotensin system Effects 0.000 claims 3
- 229960002769 zofenopril Drugs 0.000 claims 3
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims 3
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 2
- XRKXJJYSKUIIEN-LLVKDONJSA-N Pivopril Chemical compound CC(C)(C)C(=O)SC[C@@H](C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-LLVKDONJSA-N 0.000 claims 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960005025 cilazapril Drugs 0.000 claims 2
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims 2
- 229960005227 delapril Drugs 0.000 claims 2
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000001647 drug administration Methods 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 229950009810 indolapril Drugs 0.000 claims 2
- 229950009116 mevastatin Drugs 0.000 claims 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 2
- 229960002582 perindopril Drugs 0.000 claims 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 2
- 229950008688 pivopril Drugs 0.000 claims 2
- -1 seribistatin Chemical compound 0.000 claims 2
- 229960002909 spirapril Drugs 0.000 claims 2
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims 2
- 108700035424 spirapril Proteins 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000007891 compressed tablet Substances 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- 239000007942 layered tablet Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 1
- 229960003912 probucol Drugs 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/941,948 US6669955B2 (en) | 2001-08-28 | 2001-08-28 | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524552A Division JP2005504064A (ja) | 2001-08-28 | 2002-08-28 | コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012194171A Division JP2013006857A (ja) | 2001-08-28 | 2012-09-04 | コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009256381A JP2009256381A (ja) | 2009-11-05 |
| JP2009256381A5 true JP2009256381A5 (enExample) | 2011-11-17 |
Family
ID=25477337
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524552A Withdrawn JP2005504064A (ja) | 2001-08-28 | 2002-08-28 | コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形 |
| JP2009183888A Pending JP2009256381A (ja) | 2001-08-28 | 2009-08-06 | コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形 |
| JP2012194171A Pending JP2013006857A (ja) | 2001-08-28 | 2012-09-04 | コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003524552A Withdrawn JP2005504064A (ja) | 2001-08-28 | 2002-08-28 | コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012194171A Pending JP2013006857A (ja) | 2001-08-28 | 2012-09-04 | コレステロール低下薬、レニン・アンギオテンシン阻害剤およびアスピリンを含有する組み合わせ剤形 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6669955B2 (enExample) |
| EP (1) | EP1429729B1 (enExample) |
| JP (3) | JP2005504064A (enExample) |
| KR (1) | KR20040037075A (enExample) |
| CN (2) | CN1575162A (enExample) |
| AT (1) | ATE530167T1 (enExample) |
| AU (1) | AU2002336419B2 (enExample) |
| CA (1) | CA2461958C (enExample) |
| ES (1) | ES2307463T3 (enExample) |
| IL (2) | IL160643A0 (enExample) |
| NZ (1) | NZ532014A (enExample) |
| WO (1) | WO2003020243A1 (enExample) |
| ZA (1) | ZA200402417B (enExample) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6423055B1 (en) * | 1999-07-14 | 2002-07-23 | Cardiofocus, Inc. | Phototherapeutic wave guide apparatus |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US7413751B2 (en) * | 2001-10-25 | 2008-08-19 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
| WO2003084518A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules de principes actifs |
| CA2483099A1 (en) * | 2002-05-03 | 2003-11-13 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
| US20050182106A1 (en) * | 2002-07-11 | 2005-08-18 | Sankyo Company, Limited | Medicinal composition for mitigating blood lipid or lowering blood homocysteine |
| CA2492781A1 (en) * | 2002-07-11 | 2004-01-22 | Sankyo Company Limited | Medicinal composition for mitigating blood lipid or lowering blood homocystein |
| US20040115265A1 (en) * | 2002-12-11 | 2004-06-17 | Loutfy Benkerrour | Multilayered tablet containing pravastatin and aspirin and method |
| ATE424192T1 (de) * | 2003-06-26 | 2009-03-15 | Teva Pharma | Stabile pharmazeutische zubereitungen mit 2-aza- bicyclo 3.3.0 -octan-3-carboxylsäure-derivaten |
| US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| JP2006528185A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
| EP1648415A4 (en) | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
| WO2005009368A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| WO2005011586A2 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
| CA2535177A1 (en) | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
| CA2535398C (en) | 2003-08-12 | 2013-11-12 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| WO2005023184A2 (en) | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
| AU2004273830B2 (en) | 2003-09-15 | 2011-03-24 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| EP2184058B1 (en) | 2003-09-26 | 2012-02-08 | ALZA Corporation | Drug coating providing high drug loading and methods for providing the same |
| WO2005053687A1 (en) * | 2003-11-25 | 2005-06-16 | Novartis Ag | Combination of organic compounds |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| WO2006000052A1 (en) * | 2004-06-28 | 2006-01-05 | Howard J Smith & Associates Pty Ltd | Composition and method for treatment and prevention of atherosclerosis |
| EP1771158A4 (en) | 2004-07-02 | 2008-03-12 | Advancis Pharmaceutical Corp | TABLET FOR PULSE DISTRIBUTION |
| AU2005262228A1 (en) * | 2004-07-09 | 2006-01-19 | Medicure International Inc. | Combination therapies employing nicotinic acid derivatives or fibric acid derivatives |
| EP2594259A1 (en) | 2004-08-04 | 2013-05-22 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
| US20060034913A1 (en) * | 2004-08-13 | 2006-02-16 | James Gaede | Multiplex drug delivery device |
| US20060051418A1 (en) * | 2004-08-25 | 2006-03-09 | Essentialis, Inc. | Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
| US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| DE602005010899D1 (de) * | 2004-09-27 | 2008-12-18 | Sigmoid Pharma Ltd | Mikrokapseln mit einem methylxanthin und einem kortikosteroid |
| EP1879465A1 (en) * | 2005-02-09 | 2008-01-23 | Unilever N.V. | Composition comprising peptide |
| WO2006102439A2 (en) * | 2005-03-23 | 2006-09-28 | Florida Atlantic University | Treatment or prevention of cancer and precancerous disorders |
| US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
| JP2008535928A (ja) * | 2005-04-12 | 2008-09-04 | シヴィダ・インコーポレイテッド | ＨＭＧＣｏＡ還元酵素インヒビターの組合せ及びその使用 |
| US20060292225A1 (en) * | 2005-06-24 | 2006-12-28 | Felix Arthur M | Water soluble analgesic formulations and methods for production |
| EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
| US20070015839A1 (en) * | 2005-07-14 | 2007-01-18 | Franco Folli | Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome |
| CN1903364B (zh) * | 2005-07-26 | 2011-06-22 | 安徽省现代中药研究中心 | 含有血管紧张素转化酶抑制剂和苯氧酸类化合物的药物组合物 |
| JP2009503075A (ja) * | 2005-08-01 | 2009-01-29 | シヴィダ・インコーポレイテッド | ＨＭＧＣｏＡ還元酵素インヒビターコドラッグ及びその使用 |
| WO2007053406A1 (en) * | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
| US20070112593A1 (en) * | 2005-11-14 | 2007-05-17 | Rxcera Pharmaceutical, Inc. | Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| WO2007068287A1 (en) * | 2005-12-15 | 2007-06-21 | Laboratoria Qualiphar | Sustained release vitamin preparation |
| WO2007091253A2 (en) * | 2006-02-06 | 2007-08-16 | C.T.S. Ltd. | Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels |
| EP1818050A1 (de) * | 2006-02-10 | 2007-08-15 | Stada Arzneimittel Ag | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor |
| EP1825848A3 (de) * | 2006-02-10 | 2010-03-03 | Stada Arzneimittel Ag | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor |
| US20070196515A1 (en) * | 2006-02-22 | 2007-08-23 | Kothari Shil C | Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome X |
| EP2010162A4 (en) * | 2006-04-03 | 2013-01-09 | Isa Odidi | COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT |
| US20090280171A1 (en) * | 2006-04-13 | 2009-11-12 | Accu-Break Technologies, Inc. | Method of treatment with predictably breakable pharmaceutical tablets |
| MX2008013374A (es) * | 2006-04-19 | 2008-11-12 | Teva Pharma | Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3.0]-octano-3-carboxilico. |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| ES2300188B1 (es) * | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
| WO2008005543A2 (en) * | 2006-07-06 | 2008-01-10 | Teva Pharmaceutical Industries Ltd. | Compositions with controlled pharmacokinetics |
| US20080026053A1 (en) * | 2006-07-28 | 2008-01-31 | Sovereign Pharmaceuticals, Ltd. | Capsule containing granular pharmaceutical compositions |
| US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
| JP2010508266A (ja) * | 2006-10-30 | 2010-03-18 | ハナル ファーマシューティカル カンパニー リミテッド | チアジド系化合物およびアンジオテンシン−ｉｉ−受容体遮断剤を含む放出性が制御された薬学的組成物 |
| MX2009004681A (es) * | 2006-10-30 | 2009-08-19 | Hanall Pharmaceutical Co Ltd | Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa. |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| WO2008068217A2 (en) * | 2006-12-04 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
| KR100870396B1 (ko) * | 2006-12-07 | 2008-11-25 | 보령제약 주식회사 | 심혈관계 질환 치료용 경구투여제제 |
| HRP20141008T1 (hr) * | 2007-02-09 | 2015-01-02 | Alphapharm Pty Ltd | Oblik doziranja koji sadrži dva aktivna farmaceutska sastojka u razliäśitim fizikalnim oblicima |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| ES2350029T3 (es) | 2007-03-02 | 2011-01-17 | Farnam Companies, Inc. | Pellets de liberación sostenida que comprenden un material tipo cera. |
| EP2380564B1 (en) | 2007-04-04 | 2014-10-22 | Sigmoid Pharma Limited | An oral pharmaceutical composition |
| JP2010527285A (ja) | 2007-04-26 | 2010-08-12 | シグモイド・ファーマ・リミテッド | 複数のミニカプセルの製造 |
| KR100955669B1 (ko) * | 2007-08-13 | 2010-05-06 | 한올바이오파마주식회사 | ＨＭＧＣｏＡ 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법 |
| US20090082315A1 (en) * | 2007-09-05 | 2009-03-26 | Raif Tawakol | Compositions and Methods for Controlling Cholesterol Levels |
| PL2200588T3 (pl) | 2007-09-25 | 2019-09-30 | Solubest Ltd. | Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania |
| AR066168A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| EP2070520A1 (en) * | 2007-12-11 | 2009-06-17 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| JP2011510049A (ja) * | 2008-01-25 | 2011-03-31 | デュオ−ジェーウー | 包材により結合する経口医薬の組み合わせ |
| WO2009118359A2 (en) * | 2008-03-28 | 2009-10-01 | Ferrer Internacional S.A. | Capsule for the prevention of cardiovascular diseases |
| CN102088965B (zh) * | 2008-05-13 | 2013-05-08 | 根梅迪卡治疗公司 | 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用 |
| CN101590240B (zh) * | 2008-05-30 | 2012-04-25 | 北京奥萨医药研究中心有限公司 | 含血管紧张素ⅱ受体拮抗剂、他汀和叶酸的组合物及用途 |
| GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| EP2204170A1 (en) * | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising ezetimibe and simvastatin |
| CA2754134C (en) * | 2009-02-11 | 2018-09-18 | Cadila Pharmaceuticals Ltd. | Stable pharmaceutical composition for atherosclerosis |
| US8575217B2 (en) * | 2009-03-16 | 2013-11-05 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| CN102421424A (zh) * | 2009-03-16 | 2012-04-18 | 根梅迪卡治疗公司 | 用于治疗代谢性疾病的组合疗法 |
| US20120064161A1 (en) * | 2009-05-18 | 2012-03-15 | Dr. Reddy's Laboratories, Inc. | Modified release niacin pharmaceutical formulations |
| CN105213318A (zh) | 2009-05-18 | 2016-01-06 | 希格默伊德药业有限公司 | 包含油滴的组合物 |
| CN102573802A (zh) | 2009-08-12 | 2012-07-11 | 希格默伊德药业有限公司 | 包含聚合物基质和油相的免疫调节组合物 |
| CN102548544B (zh) * | 2009-10-09 | 2015-01-21 | 永进药品工业株式会社 | 同时具有速效特性和长效特性的药物组合物 |
| JP4899224B2 (ja) * | 2010-05-11 | 2012-03-21 | 春三 小林 | 動脈硬化改善剤 |
| TR201005325A2 (tr) | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
| WO2012028966A2 (en) * | 2010-07-21 | 2012-03-08 | Nucitec S.A. De C.V. | Combination dosage compositions comprising a cholesterol-lowering agent, a renin-angiotensin system inhibitor, an antioxidant agent and an antiplatelet agent for treatment and prevention of cardiovascular disease |
| US8470365B2 (en) * | 2010-07-29 | 2013-06-25 | Taiwan Biotech Co., Ltd. | Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| JP6106359B2 (ja) * | 2010-12-13 | 2017-03-29 | 第一三共ヘルスケア株式会社 | ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤 |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| PL2704698T3 (pl) * | 2011-05-05 | 2020-01-31 | Hennig Arzneimittel Gmbh&Co. Kg | Postać leku do kontrolowanego uwalniania substancji czynnych |
| KR101840086B1 (ko) * | 2011-07-15 | 2018-03-19 | 액세스 비지니스 그룹 인터내셔날 엘엘씨 | 다중카로티노이드 비들렛 및 관련 방법 |
| EP2825159B1 (en) * | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| JP6160263B2 (ja) * | 2012-06-07 | 2017-07-12 | 大正製薬株式会社 | ロキソプロフェン含有医薬組成物 |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| EP2810644A1 (en) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
| ES2524645B1 (es) * | 2013-06-06 | 2015-12-02 | Ferrer Internacional, S.A. | Formulación oral para el tratamiento de enfermedades cardiovasculares |
| EP3865120B1 (en) | 2013-07-19 | 2025-06-25 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| WO2015082389A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| CN104001176B (zh) * | 2014-06-11 | 2016-06-22 | 深圳奥萨医药有限公司 | 血小板adp受体拮抗剂和b族维生素的药物组合物 |
| DK3215127T3 (da) | 2014-11-07 | 2021-02-01 | Sublimity Therapeutics Ltd | Sammensætninger omfattende cyclosporin |
| CN107106500B (zh) | 2014-11-14 | 2021-07-30 | 伊森舍丽斯有限公司 | 用于治疗患有普拉德-威利综合征或史密斯-马吉利综合征的受试者的方法 |
| GB2533669B (en) * | 2014-12-23 | 2016-12-14 | Innovate Pharmaceuticals Ltd | Salicylate compound composition |
| BE1023011B1 (nl) * | 2015-08-05 | 2016-11-04 | Nordic Specialty Pharma Bvba | Acetylsalicylzuur tablet met onmiddellijke afgifte |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| JPWO2018124236A1 (ja) * | 2016-12-27 | 2019-11-14 | 国立大学法人大阪大学 | 難治性心疾患治療用医薬組成物 |
| WO2019109415A1 (zh) * | 2017-12-04 | 2019-06-13 | 清华大学 | 一种靶向降解hmgcr的化合物及其应用 |
| WO2020214163A1 (en) | 2019-04-17 | 2020-10-22 | CardioPharma, Inc. | Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture |
| JP2024503960A (ja) * | 2021-07-23 | 2024-01-30 | プロキャップス エスエイ | ソフトシェルゼラチンカプセル |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
| US5298497A (en) | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
| CA2040865C (en) * | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
| US5140012A (en) | 1990-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing pravastatin |
| US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| EP0622078B1 (en) | 1992-01-14 | 1999-09-01 | Hisamitsu Pharmaceutical Co., Inc. | Cholesterol level depressant |
| JP2001500875A (ja) * | 1996-09-18 | 2001-01-23 | メルク エンド カンパニー インコーポレーテッド | 心臓血管系疾患関連の危険性を減らす併用治療法 |
| US6251852B1 (en) * | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| CA2332608C (en) * | 1998-06-17 | 2010-03-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| EE05670B1 (et) | 1999-08-30 | 2013-08-15 | Aventis Pharma Deutschland Gmbh | Ramipriil kardiovaskulaarsete haigusjuhtude rahoidmiseks |
| WO2001076632A1 (en) * | 2000-04-10 | 2001-10-18 | Wald Nicholas J | Formulation for the prevention of cardiovascular disease |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
-
2001
- 2001-08-28 US US09/941,948 patent/US6669955B2/en not_active Expired - Lifetime
-
2002
- 2002-08-28 KR KR10-2004-7002962A patent/KR20040037075A/ko not_active Ceased
- 2002-08-28 JP JP2003524552A patent/JP2005504064A/ja not_active Withdrawn
- 2002-08-28 ES ES02773266T patent/ES2307463T3/es not_active Expired - Lifetime
- 2002-08-28 AT AT02773266T patent/ATE530167T1/de not_active IP Right Cessation
- 2002-08-28 EP EP02773266A patent/EP1429729B1/en not_active Expired - Lifetime
- 2002-08-28 NZ NZ532014A patent/NZ532014A/en not_active IP Right Cessation
- 2002-08-28 CN CNA028213513A patent/CN1575162A/zh active Pending
- 2002-08-28 WO PCT/US2002/027877 patent/WO2003020243A1/en not_active Ceased
- 2002-08-28 IL IL16064302A patent/IL160643A0/xx unknown
- 2002-08-28 CN CN200910148802A patent/CN101642459A/zh active Pending
- 2002-08-28 AU AU2002336419A patent/AU2002336419B2/en not_active Expired
- 2002-08-28 CA CA2461958A patent/CA2461958C/en not_active Expired - Lifetime
-
2004
- 2004-02-26 IL IL160643A patent/IL160643A/en active IP Right Grant
- 2004-03-26 ZA ZA2004/02417A patent/ZA200402417B/en unknown
-
2009
- 2009-08-06 JP JP2009183888A patent/JP2009256381A/ja active Pending
-
2012
- 2012-09-04 JP JP2012194171A patent/JP2013006857A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009256381A5 (enExample) | ||
| JP2005504064A5 (enExample) | ||
| CA2461958A1 (en) | Combination dosage form containing a cholesterol-lowering agent, a renin-angiotensin inhibitor, and aspirin | |
| JP2005041875A5 (enExample) | ||
| RU2380093C2 (ru) | Лечение и предотвращение сердечно-сосудистых заболеваний | |
| US6576256B2 (en) | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin | |
| RU2002107985A (ru) | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений | |
| MX2010010479A (es) | Capsula para la prevencion de enfermedades cardiovasculares. | |
| CN101658675A (zh) | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 | |
| JP2003238444A5 (enExample) | ||
| RU2011141908A (ru) | Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний | |
| CN100502870C (zh) | 含有瑞舒伐他汀或匹伐他汀和b族维生素的药物组合物 | |
| AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
| WO2009010810A2 (en) | Cardiovascular combinations comprising ace and hmg-co-a inhibitors | |
| RU2750934C2 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ | |
| WO2007021460A2 (en) | Method of reducing adverse cardiovascular events | |
| Maritz | Efficacy and dangers of statin therapy | |
| S. Hiremath et al. | Recent patents on oral combination drug delivery and formulations | |
| US20080118572A1 (en) | Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood | |
| MXPA06000823A (es) | Tratamiento y prevencion de eventos cardiovasculares | |
| CN101642571A (zh) | 含氨氯地平、ace抑制剂和他汀类药的药物组合物 |